#17. Daiichi-Sankyo

3-5-1 Nihombashi-honcho, Chuo-ku
Tokyo, 103-8426
Japan
Tel: (81) 3 6255 1111
Fax: (81) 3 5255 7035
www.daiichisankyo.co.jp

Headcount	98,000
Year Established	2005
PharmA Revenues	$6,944
Total Revenues	$8,194
Net Income	$776
R&D Budget	$1,404

Drugs Approved/Launched
Drug	Indication
urief	dysuria
loxonin	anti-inflammatory

Drugs in Phase IIB and Beyond
Drug	Indication
cs-747	antiplatelet agent
colesevelam	diabetes
cs-8663	hypertension
cs 917	diabetes

Early Research Projects
Drug	Indication
cs-3030	anticoagulant
cs-9803	myocardial, cerebral infarction
da-697b	novel anti-platelet
cs-7017	oncology
cs-0777	immunosuppressive

Drugs Coming Off Patent
Drug	Indication
pravastatin	antihyperlipidemic

Sales Breakdown
Region	Sales	(+/- %)
Japan	$3,818	24%
Ex-Japan	$2,562	7%

Daiichi-Sankyo has not provided sales figures for its individual drugs in 2005.